Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + recombinant human thrombopoietin
- Development stage
- Unknown
- Lead developer
- Qilu Hospital of Shandong University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
A combination therapy consisting of rituximab, a chimeric monoclonal antibody targeting CD20 on B cells, and recombinant human thrombopoietin (rhTPO), a thrombopoietin receptor agonist. This combination works through complementary mechanisms - rituximab depletes B cells and reduces autoantibody production that causes platelet destruction, while rhTPO stimulates platelet production by binding to the thrombopoietin receptor and activating the JAK2/STAT5 pathway. The combination has shown superior efficacy compared to rituximab monotherapy in treating immune thrombocytopenia (ITP), with higher complete response rates (45.4% vs 23.7%) and significantly shorter time to response (median 7 days vs 28 days).
- Brand names
- TPIAORituxanMabThera
- Other names
- rhTPO + rituximabrituximab + rhTPOTPO-RA + rituximab
02
Targets
Beyond the preview
Go deeper on rituximab + recombinant human thrombopoietin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + recombinant human thrombopoietin.